William Blair & Company
DNLI icon

William Blair & Company’s Denali Therapeutics DNLI Stock Holding History

William Blair & Company’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,100
Closed -$227K – 1926
2021
Q4 		$227K Hold
5,100
– – ﹤0.01% 1518
2021
Q3 		$257K Hold
5,100
– – ﹤0.01% 1391
2021
Q2 		$400K Hold
5,100
– – ﹤0.01% 1235
2021
Q1 		$291K Sell
5,100
-100
-2% -$6.69K ﹤0.01% 1337
2020
Q4 		$436K Buy
+5,200
New +$314K ﹤0.01% 1125

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

William Blair & Company's DNLI Position: Q1 2022 in Review

William Blair & Company sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 5,100 shares — an estimated $227K sold.

William Blair & Company first reported a position in DNLI in Q4 2020 and held it in 5 quarters. The position peaked at $436K in Q4 2020. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • William Blair & Company reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
  • William Blair & Company sold 5,100 Denali Therapeutics shares in Q1 2022, an estimated $227K.
  • William Blair & Company first reported a position in Denali Therapeutics in Q4 2020 and held it in 5 quarters.
  • William Blair & Company's Denali Therapeutics position peaked at $436K in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.